Search results
Showing 2671 to 2685 of 9071 results
Familial Breast Cancer: initial assessment and genetic testing (update)
In development Reference number: GID-NG10438 Expected publication date: 22 April 2027
We are listening to your views on this NICE guideline. Comments close 10 July 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 17 July 2026.
We are listening to your views on this HealthTech guidance. Comments close 3 July 2026.
Awaiting development Reference number: GID-TA12452 Expected publication date: TBC
Orforglipron for managing overweight and obesity in people 12 to 17 years
Awaiting development Reference number: GID-TA12451 Expected publication date: TBC
Divarasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer
Awaiting development Reference number: GID-TA12450 Expected publication date: TBC
Niraparib for treating newly diagnosed unmethylated glioblastoma
Awaiting development Reference number: GID-TA12449 Expected publication date: TBC
In development Reference number: GID-HTG10887 Expected publication date: 13 October 2026
Awaiting development Reference number: GID-TA12448 Expected publication date: TBC
Cagrilintide–semaglutide for managing overweight and obesity
Awaiting development Reference number: GID-TA12443 Expected publication date: TBC
Ivonescimab for untreated metastatic non-small-cell lung cancer with high PD-L1 expression
Awaiting development Reference number: GID-TA12444 Expected publication date: TBC
In development Reference number: GID-HTG10902 Expected publication date: TBC
In development Reference number: GID-HTG10886 Expected publication date: 04 February 2027
Lutikizumab for treating moderate to severe hidradenitis suppurativa in people 12 years and over
Awaiting development Reference number: GID-TA12446 Expected publication date: TBC